• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 8.680
Bid (Size) 8.680 (100)
Ask (Size) 8.800 (114)
Prev. Close 8.680
Today's Range 8.680 - 8.680
52wk Range 5.401 - 9.360
Shares Outstanding 59,762,106
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sage (SAGE) Q2 Revenue Jumps 264% ↗
August 01, 2025
Via The Motley Fool
News headline image
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
July 31, 2025
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to... 
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
-5.7%
-5.7%
1 Year
+50.2%
+50.2%

More News

Read More
News headline image
Sage Therapeutics Announces Second Quarter 2025 Financial Results
July 30, 2025
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
July 28, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
July 25, 2025
From Biogen Inc.
Via GlobeNewswire
News headline image
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
July 14, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗
July 10, 2025
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock ↗
July 08, 2025
Via Benzinga
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders
July 05, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 27, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
July 01, 2025
From FN Media Group LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, CHTR, SAGE, TASK on Behalf of Shareholders
June 25, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
July 01, 2025
Via FinancialNewsMedia
Topics Death
News headline image
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
June 23, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms ↗
June 22, 2025
Via Stocktwits
News headline image
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
June 18, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Deep Dive Into Sage Therapeutics Stock: Analyst Perspectives (4 Ratings) ↗
June 17, 2025
Via Benzinga
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders
June 17, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News ↗
June 17, 2025
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 17, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs ↗
June 17, 2025
Via Benzinga
News headline image
US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert ↗
June 17, 2025
Via Benzinga
Topics Government
News headline image
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone ↗
June 17, 2025
Via Benzinga
Topics Stocks
News headline image
Monday's session: top gainers and losers ↗
June 16, 2025
Via Chartmill
News headline image
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June ↗
June 16, 2025
Via Benzinga
Topics Stocks

Frequently Asked Questions

Is Sage Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sage Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sage Therapeutics, Inc. - Common Stock trade on?
Sage Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sage Therapeutics, Inc. - Common Stock?
The ticker symbol for Sage Therapeutics, Inc. - Common Stock is SAGE on the Nasdaq Stock Market
What is the current price of Sage Therapeutics, Inc. - Common Stock?
The current price of Sage Therapeutics, Inc. - Common Stock is 8.680
When was Sage Therapeutics, Inc. - Common Stock last traded?
The last trade of Sage Therapeutics, Inc. - Common Stock was at 07/30/25 04:00 PM ET
What is the market capitalization of Sage Therapeutics, Inc. - Common Stock?
The market capitalization of Sage Therapeutics, Inc. - Common Stock is 518.74M
How many shares of Sage Therapeutics, Inc. - Common Stock are outstanding?
Sage Therapeutics, Inc. - Common Stock has 519M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap